Heather Beckwith, MD
Medical Oncology · Maple Grove, MNNPI 1780879940
Payments from drug & device makers
What this record shows
This record is dominated by grants: $350 of the $362 with a category attached, or 96.7%. AstraZeneca accounts for 96.7% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for medical oncology clinicians in MN, where the typical reported total is $1,006.
Across 2 payments — averaging $180.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$350
- Gilead$12
Across 91 payments — averaging $19,208 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$959K
- Boehringer Ingelheim$569K
- Seagen Inc.$147K
- Puma Biotechnology, Inc.$62K
- AstraZeneca$9K
- Boehringer Ingelheim International GmbH$1K
What the payments were for
- Grants$35097%
- Education$123%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 1 | $350 |
| Gilead | 1 | $12 |
How this compares
$362 in reported general payments places this provider in the 40th percentile of 133 medical oncology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 20 | $314,399 |
| XareltoRivaroxaban | 14 | $9,497 |
| Letrozole | 158 | $3,813 |
| Anastrozole | 128 | $2,633 |
| Exemestane | 45 | $2,109 |
| Tamoxifen Citrate | 38 | $622 |
| Gabapentin | 19 | $200 |
| Levothyroxine Sodium | 11 | $191 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 13 | $107 |
| Ibuprofen | 12 | $91 |
| Zolpidem Tartrate | 15 | $79 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Maple Grove
- Joseph LeachMaple Grove$6K
- Amy KrieMinneapolis$907K
- Amit MahipalRochester$746K
- Alton SartorRochester$688K
- Ben GeorgeRochester$579K
- Noel LaudiCoon Rapids$274K
- Emmanuel AntonarakisMinneapolis$260K
- Elisabeth HeathRochester$236K
- Matthew GoetzRochester$136K
- Charles RyanMinneapolis$99K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.